17/02/2026
Role of Lactate Dehydrogenase (LDH) in Hematology
Lactate dehydrogenase (LDH) is an intracellular enzyme present in almost all body tissues, particularly abundant in red blood cells, leukocytes, platelets, liver, muscle, and bone marrow. Because it is released into the bloodstream when cells are damaged or destroyed, LDH serves as a sensitive but nonspecific biochemical marker of tissue turnover. In hematology, LDH is extremely valuable as a surrogate indicator of cell proliferation, hemolysis, and tumor burden.
One of the most important uses of LDH is in the evaluation of hemolytic anemia. Red blood cells contain very high concentrations of LDH; therefore intravascular or extravascular hemolysis leads to a marked rise in serum LDH. When interpreted along with indirect bilirubin, reticulocyte count, and haptoglobin levels, LDH helps confirm active hemolysis and monitor response to treatment. A falling LDH often indicates control of hemolysis.
LDH is also a crucial prognostic marker in hematological malignancies. In leukemias and aggressive lymphomas, rapid cellular turnover releases large quantities of LDH into circulation. Higher LDH levels generally correlate with tumor burden, disease aggressiveness, and risk of complications such as tumor lysis syndrome. During therapy, declining LDH suggests good treatment response, whereas rising levels may signal relapse or refractory disease even before clinical deterioration becomes obvious.
In plasma cell disorders, LDH has special significance. Elevated LDH in multiple myeloma often indicates high-risk disease biology and extramedullary involvement. Similarly, in myeloproliferative neoplasms and myelodysplastic syndromes, LDH reflects marrow turnover and ineffective hematopoiesis.
LDH is also useful in thrombotic microangiopathies such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, where severe intravascular hemolysis produces striking elevation. Serial monitoring helps assess disease activity and response to plasma exchange.
Although LDH lacks disease specificity, its strength lies in trend interpretation. A single value has limited meaning, but dynamic changes provide powerful clinical insight. Thus, LDH remains a simple, inexpensive, and widely available biomarker that assists diagnosis, prognostication, and therapeutic monitoring across a broad spectrum of hematological disorders.
